CIITA Antibody is affinity chromatography purified via peptide column.
Immunogen
CIITA antibody was raised against a 16 amino acid synthetic peptide near the amino terminus of human CIITA. The immunogen is located within amino acids 120 - 170 of CIITA.
CIITA antibody can be used for detection of CIITA by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in rat samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
CIITA Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
CIITA antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
CIITA
(Class II, Major Histocompatibility Complex, Transactivator (CIITA))
CIITA antibody, C2ta antibody, EG669998 antibody, Gm9475 antibody, C2TA antibody, CIITAIV antibody, MHC2TA antibody, NLRA antibody, Mhc2ta antibody, class II, major histocompatibility complex, transactivator antibody, class II major histocompatibility complex transactivator antibody, MHC class II transactivator antibody, class II transactivator antibody, CIITA antibody, LOC710761 antibody, ciita antibody, LOC100443575 antibody, Ciita antibody, LOC100736732 antibody
Background
CIITA Antibody: CIITA contains an acidic transcriptional activation domain, four LRRs (leucine-rich repeats) and a GTP binding domain. It is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. CIITA also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.